Skip to contentA
Amphastar Pharmaceuticals, Inc.
A
AMPHAmphastar Pharmaceuticals, Inc. Q2 2017 · 10-Q
Revenue$65.19M$65.19M−4.2% vs Q2 2016 Net Income$1.97M$1.97M−71.4% vs Q2 2016 EPS Diluted$0.04$0.04−73.3% vs Q2 2016 Gross Profit$26,659,000−15.9% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Amphastar Pharmaceuticals, Inc. · CIK 1297184 · Engraved from SEC EDGAR
Operating Cash Flowderived$4,574,000−51.0% Free Cash Flowderived-$1,727,000N/M Margins · derivedGross margin40.9%−5.7 pt vs Q2 2016
Operating margin3.4%−11.8 pt vs Q2 2016
Net margin3.0%−7.1 pt vs Q2 2016
ended Jun 30, 2017 · filed Aug 9, 2017 · 40 d after period end